Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
30 10월 2023 - 9:30PM
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global
clinical-stage biopharmaceutical company dedicated to developing
innovative and highly efficacious cell therapies for the treatment
of cancer and autoimmune diseases, today announced that it plans to
release unaudited financial results for the third quarter ended
September 30, 2023 and provide an update on recent developments
prior to the open of the U.S. financial markets on Monday, November
13, 2023. The management team will host a live audio webcast and
conference call at 8:00 AM Eastern Time.
Conference call and webcast details:Monday,
November 13, 2023 @ 8:00am ETInvestor domestic dial-in: (800)
715-9871 Investor international dial-in: +1 (646)
307-1963Conference ID: 3201224
Live webcast
link: https://ir.gracellbio.com/news-events/events-and-presentations
A replay of the webcast will be available
on ir.gracellbio.com shortly after the conclusion of the
event for 90 days.
About GracellGracell Biotechnologies Inc.
(“Gracell”) is a global clinical-stage biopharmaceutical company
dedicated to discovering and developing breakthrough cell therapies
for the treatment of cancers and autoimmune diseases. Leveraging
its innovative FasTCAR and TruUCAR technology platforms and SMART
CART™ technology module, Gracell is developing a rich
clinical-stage pipeline of multiple autologous and allogeneic
product candidates with the potential to overcome major industry
challenges that persist with conventional CAR-T therapies,
including lengthy manufacturing time, suboptimal cell quality, high
therapy cost, and lack of effective CAR-T therapies for solid
tumors and autoimmune diseases. The lead candidate BCMA/CD19
dual-targeting FasTCAR-T GC012F is currently being evaluated in
clinical studies for the treatment of multiple myeloma, B-NHL and
systemic lupus erythematosus (SLE). For more information on
Gracell, please visit www.gracellbio.com. Follow @GracellBio on
LinkedIn.
Media contacts
Marvin Tang
marvin.tang@gracellbio.com
Jessica Laub
jessica.laub@westwicke.com
Investor contacts
Gracie Tong
gracie.tong@gracellbio.com
Stephanie Carrington
stephanie.carrington@westwicke.com
Gracell Biotechnologies (NASDAQ:GRCL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Gracell Biotechnologies (NASDAQ:GRCL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024